Analytical Data
-
Gene name
FOLR4
- Application
-
Alternative Names
Folbp3; IZUMO1R; JUNO; Sperm-egg fusion protein Juno; Folate receptor delta; IZUMO1 receptor protein JUNO
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9EQF4
-
Expression Region
Cys56~Pro234
-
Molecular Weight
25kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FOLR4 (Folate receptor 4) is a member of the folate receptor family, which plays a crucial role in folate uptake and transport in various cell types. It is primarily expressed in the placenta, kidney, and certain cancer tissues, making it a potential target for therapeutic interventions, particularly in cancer research. Studies have demonstrated that FOLR4 is involved in important biological processes, including cell proliferation, differentiation, and immune response modulation. Due to its overexpression in several tumors, such as ovarian cancer and certain leukemias, FOLR4 has garnered significant attention as a biomarker for cancer diagnosis and prognosis. The study of recombinant FOLR4 proteins provides valuable insights into the receptor's structure-function relationships, enhancing our understanding of its mechanisms in cellular signaling pathways. Additionally, the development of FOLR4-targeted therapies, such as antibody-drug conjugates, showcases its potential as a novel approach for targeted cancer treatment. Given the impact of FOLR4 in both health and disease, ongoing research into its recombinant forms aims to unlock new diagnostic and therapeutic avenues in oncology and beyond.
